skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 2016, Flexion Therapeutics CEO Mike Clayman is hoping for priority review of the filing, in addition to fast track status. Zilretta is an extended release formulation of the triamcinolone acetonide. Steroid injection is a common treatment, but pain relief wanes after two to four weeks. Competing against generic steroids, which cost only USD 10–20 per dose, presents a big commercial challenge however. In an interview at Biotech Showcase, Clayman explains the rationale for pricing a long-acting steroid at USD 500 per dose and the company's commercial strategy.


Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or email us your inquiry, so we can provide you the best possible customer service:

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: